Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group Trial [Melanoma]

Conclusion
Although the safety and QoL profiles for the intermittent regimen were favorable, no significant difference was observed for survival while the HR for relapse with iHDI was increased. Therefore, an iHDI regimen, as tested here, cannot be recommended as adjuvant treatment for high-risk melanoma.

Source: Journal of Clinical Oncology - November 25, 2015 Category: Cancer & Oncology Authors: Mohr, Hauschild, Trefzer, Enk, Tilgen, Loquai, Gogas, Haalck, Koller, Dummer, Gutzmer, Brockmeyer, Holzle, Sunderkotter, Mauch, Stein, Schneider, Podda, Goppner, Schadendorf, Weichenthal Tags: Combined Modality Melanoma Source Type: research